Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer

American Journal of Therapeutics

Volumn 16, Issue 2, 2009, Pages 127-132

  Papatheofanis, Frank J ^a   Smith, Cynthia ^b   Najib, Mohammad ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Aequitas   (United States)

Author keywords

Assessment; Cancer; Pain; Prostate; Quality of life; Radionuclide; Samarium lexidronam

Indexed keywords

ACETYLSALICYLIC ACID; FENTANYL; IBUPROFEN; LEUPRORELIN; LEXIDRONAM SAMARIUM SM 153; MORPHINE; NAPROXEN; OPIATE; OXYCODONE; RADIOISOTOPE; STRONTIUM 89;

ADVANCED CANCER; AGED; ARTICLE; CONTROLLED STUDY; DRUG SELF ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; SHORT TERM MEMORY; STUDENT T TEST;

AGED; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; STRONTIUM; TIME FACTORS;

EID: 64549111381     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31816ddb5d     Document Type: Article

References (38)

1. American Cancer Society. Cancer Facts and Figures, 2007. Atlanta, GA: American Cancer Society; 2007.
2. Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Semin Urol Oncol. 2002;20:3-9.
3. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol. 1991;18(4 Suppl 5):11-15.
4. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev. 1996;22:289-331.
5. Shannon MM, Ryan MA, D'Agostino N, et al. Assessment of pain in advanced cancer patients. J Pain Symptom Manage. 1995;10:274-278.
6. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277-299.
7. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984;2:472-83.
8. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11: 570-579.
9. Berger A, Dukes E, Smith M, et al. Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life. J Pain Symptom Manage. 2003;26:723-730.
10. Van Andel G, Visser AP, Hulshof MC, et al. Health-related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. BJU Int. 2003;92:217-222.
11. Abbas SQ, Abbas Z. Is opiate compliance a problem in cancer pain? A survey of health-care professionals' views. Int J Palliat Nurs. 2 003;9:56-63.
12. Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev. 2003;29:321-327.
13. Oosterhof GO, Roberts JT, de Reijke TM, et al. Stron-tium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003;44:519-526.
14. Bauman G, Charette M, Reid R, et al. Radiopharmaceuticals for the palliation of painful bone metastasisa systemic review. Radiother Oncol. 2005;75:258-270.
15. Green CR, Wheeler JR. Physician variability in the management of acute postoperative and cancer pain: a quantitative analysis of the Michigan experience. Pain Med. 2003;4:8-20.
16. Green CR, Wheeler JR, LaPorte F. Clinical decision making in pain management: contributions of physician and patient characteristics to variations in practice. J Pain. 2003;4:29-39.
17. Papatheofanis FJ. Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy. J Nucl Med. 1999;40:1420-1423.
18. Dudgeon D, Raubertas RF, Rosenthal SN. The short-form McGill Pain Questionnaire in chronic cancer pain. J Pain Symptom Manage. 1993;8:191-195.
19. Graham C, Bond SS, Gerkovich MM, et al. Use of the McGill pain questionnaire in the assessment of cancer pain: replicability and consistency. Pain. 1980;8: 377-387.
20. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989;30:1814-1818.
21. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;(46 Suppl 1):38S-47S.
22. Management of cancer pain: adults. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin. 1994;9:1-29.
23. McNicol E, Strassels S, Goudas L, et al. Nonsteroidal antiinflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. J Clin Oncol. 2004;22:1975-1992.
24. Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol. 1994;12:2756-2765.
25. World Health Organization. Cancer pain relief and palliative care: .report of a WHO expert committee.(Technical Report Series 804). Geneva, Switzerland: WHO, 1990.
26. Agency for Health Care Policy and Research. Management of cancer pain: adults. Cancer Pain Guideline Panel. Am Fam Physician. 1994;49:1853-1868.
27. Tuma R, DeAngelis LM. Altered mental status in patients with cancer. Arch Neurol. 2000;57:1727-1731.
28. Von Roenn JH, Cleeland CS, Gonin R, et al. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med. 1993;119:121-126.
29. Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993; 20(3 Suppl 2):38-43.
30. FDA Professional Drug Information Database: Metastron (Strontium-89 Chloride), http://www.drugs.com/pro/Metastron.html. Accessed February 2006.
31. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14:135-143.
32. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-945.
33. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
34. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993; 34:1839-1844.
35. Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of 153Sm-emylenediaminetetramethylenephosphonate OEDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583-1591.
36. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer. 2000;88(12 Suppl):2934-2939.
37. Tripathi M, Singhal T, Chandrasekhar N, et al. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J Cancer. 2006;43:86-92.
38. Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109: 637-43.